Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Print this page Email this page Users Online: 266

  Table of Contents  
COMMENTARY
Year : 2020  |  Volume : 13  |  Issue : 3  |  Page : 208-209  

Hydroxychloroquine, COVID-19, and prophylaxis


Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India; partment of Community Medicine, Hainan Medical University, Haikou, China; Department of Community Medicine, Faculty of Medicine, University of Nis, Nis, Serbia; Department of Community Medicine, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria

Date of Submission01-May-2020
Date of Decision08-May-2020
Date of Acceptance08-May-2020
Date of Web Publication3-Jun-2020

Correspondence Address:
Viroj Wiwanitkit
Professor, Dr. DY Patil University, Pune, Maharashtra

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mjdrdypu.mjdrdypu_226_20

Rights and Permissions

How to cite this article:
Wiwanitkit V. Hydroxychloroquine, COVID-19, and prophylaxis. Med J DY Patil Vidyapeeth 2020;13:208-9

How to cite this URL:
Wiwanitkit V. Hydroxychloroquine, COVID-19, and prophylaxis. Med J DY Patil Vidyapeeth [serial online] 2020 [cited 2020 Jul 5];13:208-9. Available from: http://www.mjdrdypv.org/text.asp?2020/13/3/208/285764



As a new emerging infection, the effective treatment for COVID-19 is still unavailable. There are several attempts to find new drugs to manage this infection. At the same time, there are attempts to use classical available drug for trial treatment of the patients. Many drugs including antiretroviral drugs, antibiotics, antimalarial drug, and hydroxychloroquine are presently being tested for efficacy in treatment of COVID-19. Hydroxychloroquine is one of the drugs mentioned for its effectiveness in COVID-19 patients. Presently, this drug is used in rheumatology for treating systemic lupus erythematosus (SLE) and patients with other autoimmune conditions. The extremely low incidence of COVID-19 among patients with underlying SLE is an important clue triggering the study of efficacy of hydroxychloroquine against COVID-19.[1]

If hydroxychloroquine is used for treatment of patients with COVID-19, effectiveness of the drug is the main parameter to be evaluated. In addition, the safety of the drug has to be verified. Meyerowitz et al. noted that the drug “should only be used with caution and in the context of carefully thought out clinical trials, or on a case-by-case basis after rigorous consideration of the risks and benefits of this therapeutic approach.[2]” In the above study,[3] the safety of the drug is reported. According to this study on “Adverse drug reaction profile of prophylactic hydroxychloroquine for COVID-19 amongst doctors,” there is no serious adverse reaction of the drug in the sample of doctors observed.

In fact, the risk of using hydroxychloroquine for treatment of COVID-19 is an important issue to be addressed. The single use or combination with antibiotics such as azithromycin might cause clinical problem.[4] An important basic risk of using hydroxychloroquine is the triggering of hemolytic episode in patients with underlying glucose-6-phosphate dehydrogenase (G6PD) deficiency.[5] This is a common genetic disorder in many areas of the world; the risk in these regions should be kept in mind. Another important risk of using hydroxychloroquine for COVID-19 treatment is cardiac complication. Acquired long QT syndrome is a possible adverse effect due to proarrhythmic effects of hydroxychloroquine.[6],[7] A rarer unwanted adverse effect on hepatic function is also reported on using hydroxychloroquine in patients with COVID-19. Using hydroxychloroquine is reported for possible induction of “10-fold increase in serum levels of transaminases” in COVID-19 patients.[8] When used for prophylaxis in people with cardiac and hepatic conditions, monitoring of electrocardiogram and liver function tests is recommended.

However, since hydroxychloroquine is a classical drug that is not expensive and is already adapted in management of many clinical problems such as diabetes, Singh et al. noted that it is “worthy of fast-track clinical trial for treatment, and may be carefully considered for clinical use as experimental drug.[9]” At least, if hydroxychloroquine is selected for treatment of patients with COVID-19, a simple test for G6PD deficiency is required before starting of hydroxychloroquine. Finally, if the drug is finally confirmed for effectiveness and safety, the further issue to be studied is the proper dosage for use in management of COVID-19.



 
  References Top

1.
Joob B, Wiwanitkit V. SLE, hydroxychloroquine and no SLE patients with covid-19: A comment. Ann Rheum Dis 2020;79:e61.  Back to cited text no. 1
    
2.
Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 2020;34:6027-37.  Back to cited text no. 2
    
3.
Kulkarni RK, Kinikar AA, Jadhav T. Adverse drug reaction profile of prophylactic Hydroxychloroquine for COVID-19 amongst doctors. Med J Dr DY Patil Vidyapeeth 2020;13:3.  Back to cited text no. 3
    
4.
Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C. COVID-19 and (hydroxy) chloroquine-azithromycin combination: Should we take the risk for our patients? Br J Clin Pharmacol 2020. [Doi: 10.1111/bcp.14335].  Back to cited text no. 4
    
5.
Beauverd Y, Adam Y, Assouline B, Samii K. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol 2020;10. doi:10.1111/ejh.13432.  Back to cited text no. 5
    
6.
Tomcsányi J, Tomcsányi K. Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine. Orv Hetil 2020;161:689-91.  Back to cited text no. 6
    
7.
Lentini G, Cavalluzzi MM, Habtemariam S. COVID-19, Chloroquine repurposing, and cardiac safety concern: Chirality might help. Molecules 2020;25:1834.  Back to cited text no. 7
    
8.
Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. Case report: Hepatotoxicity associated with the use of hydroxychloroquine in a patient with novel coronavirus disease (COVID-19). Am J Trop Med Hyg 2020. doi:10.4269/ajtmh.20-0276.  Back to cited text no. 8
    
9.
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020;14:241-6.  Back to cited text no. 9
    




 

Top
   
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed148    
    Printed1    
    Emailed0    
    PDF Downloaded68    
    Comments [Add]    

Recommend this journal